Weight Watchers Report Finds Integrated GLP-1 Support Drives Significantly Greater Weight Loss Than Medication Alone




Weight Watchers Report Finds Integrated GLP-1 Support Drives Significantly Greater Weight Loss Than Medication Alone

Weight Watchers’ Med+ members who regularly engaged with their GLP-1 Success Program lost up to 61% more body weight in the first month and 29% more in one year, on average, than those who took medication alone.

Med+ members prescribed medication also reported, on average, over 30% more weight loss than select competitors at 12 months.

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today released a GLP-1 Results Report which finds that individuals who take GLP-1 medications and regularly engage in the Weight Watchers GLP-1 Success Program achieved significantly greater weight loss and better health outcomes than those using medication alone. The Weight Watchers evidence review builds on a growing body of research on long-term weight management. For example, a recent systematic review published in the British Medical Journal found that weight regain commonly occurs after discontinuation of anti-obesity medications, while guidance from the World Health Organization continues to emphasize the role of nutrition, physical activity, and other lifestyle factors in supporting metabolic health.

“GLP-1 medications are transforming obesity care — but a growing body of research is proving that medication alone is not enough to create lasting results,” said Weight Watchers CEO Tara Comonte. “To maximize the impact of these medical breakthroughs, Weight Watchers has established an integrated weight health platform that combines medication with structured nutritional, behavioral, and lifestyle supports. The results speak for themselves: members who pair weight loss medication with Weight Watchers’ GLP-1 Success Program lose up to 61% more weight in the first month and nearly 30% more weight over a year, on average, compared to those who do not engage with our approach. Clearly, GLP-1s work better with Weight Watchers.”

Weight Watchers’ Med+ platform, combined with the GLP-1 Success Program, offers access to board-certified physicians, FDA-approved prescriptions, and lifestyle support to drive better outcomes and create lasting habits that can sustain results over time. Designed to specifically address side effects, nutrition gaps, muscle loss, and plateaus, the program helps members stay consistent with the tools they need for success throughout their GLP-1 journey.

The GLP-1 Results Report also identified benefits beyond the scale. Additional clinical and real-world evidence cited show that Weight Watchers programs are associated with improvements in important health and behavioral measures — including hemoglobin A1c, blood pressure, diet quality, physical activity, and quality of life — that support long-term health and sustainability.

In the Weight Watchers app, members can track nutrition, follow guided fitness and strength-focused movement sessions, connect with others on GLP-1s, access dietitians, and discover easy recipes and meal plans — supporting sustainable weight loss and maintaining muscle. The membership also offers a variety of workshops led by physicians, registered dietitians, and Weight Watchers-trained coaches to help members maximize the impact of their GLP-1s.

The key findings in the GLP-1 Results Report illustrate:

Clinical and Real-World Findings

• Weight Watchers Med+ members prescribed GLP-1 medications lost 7.4 pounds in the first four weeks, and reached 21% average weight loss at 12 months and 20.5% average weight loss at 24 months.
• Among Weight Watchers Med+ members, those who actively engaged with the GLP-1 Success Program lost 61.3% more body weight after just one month compared with members who did not engage in additional support.
  • The advantage continued over time. Weight Watchers Med+ members who regularly engaged with the GLP-1 Success Program consistently lost more weight than those who did not engage in additional support — with improved outcomes observed at 3, 6, and 12 months, underscoring the value of combining medication with structured lifestyle guidance.
• Weight Watchers Med+ members prescribed GLP-1 medications reported, on average, over 30% more body weight loss than select competitors at 12 months.
• In one comparative analysis, members achieved 72% greater average weight loss than a cohort receiving compounded GLP-1 medications through Hims & Hers.

Reducing Side Effects and Supporting Sustainability

• Nearly 72% of members on the Weight Watchers GLP-1 Success Program reported that the program helped minimize GLP-1 side effects, which can support better adherence and long-term success.
• Among members prescribed obesity medication through the Med+ Program, who began treatment with high blood pressure, 87% had normal blood pressure after 12 months.
• The GLP-1 Success Program also emphasizes evidence-based nutrition targets like protein, fiber, and hydration, helping to preserve muscle mass, reduce gastrointestinal discomfort, and support adequate nutrient intake during weight loss.

Scalable Impact for the Future of Weight Health

• 75% of members report improved confidence and quality of life.
• 71% of members say the program helped them become the healthiest version of themselves.
• 81% say Weight Watchers has changed their life for the better.

ABOUT WEIGHT WATCHERS
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

For media inquiries, please contact:
Lizzy Levitan
WW@hunt-gather.com 

For investor inquiries, please contact:
John Mills or Anna Kate Heller
WeightWatchers@icrinc.com 

Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic




Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic

• Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher Bio
• Follows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine release
• Commit is poised to nominate its first two clinical development candidates later in 2026

COPENHAGEN, Denmark, March 11, 2026 (GLOBE NEWSWIRE) — Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in seed financing from Novo Holdings, Bioqube Ventures, and Korys, today announces the appointment of seasoned biotech entrepreneur Thomas L. F. Montgomery Andresen, PhD, as Chief Executive Officer. Dr. Andresen joins at a pivotal juncture to accelerate Commit’s transition into a clinical-stage company.

Dr. Andresen is a serial biotech entrepreneur with over 20 years of experience building high-value biotech ventures at the intersection of therapeutic innovation and bioengineering. He brings a proven track record of converting scientific breakthroughs into marketable technologies and has played an instrumental role in securing substantial institutional backing to launch and scale multiple biotechnology companies across Europe and the U.S.

Dr. Andresen will officially assume his role on March 16, 2026.

Anker Lundemose, Chairman of the Board at Commit Biologics, said: “Thomas’ rare combination of deep scientific expertise and strategic leadership as a serial biotech founder makes him exceptionally qualified to lead Commit into its next phase of growth. His appointment is a defining step on our journey to deliver transformative immunotherapies and strengthens our position as a leader in complement-targeting innovation.”

Dr. Andresen, incoming CEO of Commit Biologics, said: “Commit is redefining immunotherapy by activating the complement system – one of the immune system’s most potent, yet untapped weapons. Since the turn of the century, the immunotherapy field has produced a series of breakthrough modalities, from checkpoint inhibitors to CAR-Ts and T-cell engagers. Commit is at the forefront of what I firmly believe to be the next breakthrough modality: complement-powered immune engagers. The Company’s preclinical data is outstanding, and its non-human primate data, in particular, gives me the strong conviction that these positive results will be replicated in the clinic.

“I want to thank Chief Scientific Officer Mikkel Wandahl Pedersen for his steadfast leadership as Interim CEO. Having established strong momentum and a validated platform, I look forward to working with Mikkel and the team to deliver life-changing therapies for patients.”

Commit is currently advancing a pipeline of proprietary therapeutics powered by its Bispecific Complement Engager (BiCE™) technology platform. In November 2025, the Company announced positive proof-of-concept data from a non-human primate (NHP) study, providing critical translational validation of the BiCE™ platform. Results demonstrated rapid, deep, and sustained targeted B-cell depletion without triggering systemic cytokine release – establishing solid safety and efficacy profiles and proof-of-mechanism.

Commit is poised to nominate its first two clinical development candidates (DCs) in 2026, which will address key unmet needs in autoimmune disease and oncology. These DCs lead a broader pipeline targeting strategic clinical entry points, focusing on patients with compromised T-cell function, and indications where the differentiated mechanism of action offers new high-value treatment possibilities.

Prior to joining Commit, Dr. Andresen co-founded several successful biotechs, including Flagship Pioneering-backed Torque Therapeutics, which was acquired by Repertoire Immune Medicines. Most recently, he served as founding CEO of T-Cypher Bio, an Oxford, UK-based immunotherapy company backed by LifeArc, Oxford Science Enterprises (OSE), and Medicxi.

Additionally, he was founding director of DTU Health Tech at the Technical University of Denmark (DTU). He has authored 220+ scientific papers and is a named inventor on 50+ patent families across a diverse range of therapeutic applications.

For more information please contact:

Optimum Strategic Communications
Nick Bastin, Stephen Adams, Aoife Minihan
Tel: +44 (0) 204 566 8543
Email: commit@optimumcomms.com

About Commit Biologics

Commit Biologics is a biotechnology company transforming the treatment of autoimmune diseases and cancer by activating the complement system. The company’s proprietary Bispecific Complement Engager (BiCE™) platform is producing a new class of immune engagers that directly recruit the complement cascade to target cells. BiCE™ antibodies supercharge the innate immune response, rapidly eliminating diseased cells locally without triggering systemic immune activation. With positive NHP proof-of-concept data and €21.5 million in seed financing from Novo Holdings, Bioqube Ventures, and Korys, Commit is advancing toward clinical entry and defining the next era of immune therapeutics.

About the complement system

The complement system is a powerful pillar of the innate immune system, acting as a first line of defense to identify and eliminate pathogens or damaged cells. While it is one of the body’s most effective killing mechanisms, harnessing its potential for targeted therapy represents a major frontier in immuno-engineering. Controlling this activation offers a novel therapeutic approach across autoimmune, inflammatory, and malignant diseases.

Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement




Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

• The agreement enables a full tech transfer of the chikungunya vaccine for future supply to low- and middle-income countries.
• Expanded collaboration provides future co-development opportunities.

COPENHAGEN, Denmark, March 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine (CHIKV VLP) from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic low- and middle-income countries (LMICs). This agreement builds on the existing mpox vaccine license and manufacturing agreement with SII, and replaces the agreement previously entered with Biological E. Limited.

In addition, through this expanded collaboration, the parties will explore potential future co-development opportunities.

“We are pleased to strengthen our strategic partnership with Serum Institute of India. By leveraging the strengths of both organizations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the globe,” said Paul Chaplin, President & CEO of Bavarian Nordic.

About CHIKV VLP
CHIKV VLP is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as 1 week after vaccination.

The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, ensuring a broad range of people can benefit from vaccination.

CHIKV VLP (marketed as Vimkunya^®) has been approved by the U.S. Food and Drug Administration, the European Commission and the U.K. Medicines & Healthcare products Regulatory Agency in 2025. Regulatory review of the vaccine is ongoing in Switzerland and Canada.

About chikungunya
Chikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries¹. Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years². In 2025, as of December, nearly 500,000 cases of chikungunya and over 200 associated deaths were reported worldwide³. More than half of the reported cases and associated deaths were reported from Brazil⁴. Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile⁵.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com.

About Serum Institute of India
Serum Institute of India Pvt. Ltd. is the world’s largest vaccine manufacturer, developing life-saving vaccines against diseases including polio, measles, meningitis, rotavirus, diphtheria, tetanus, malaria, HPV, pneumonia, and COVID-19, with a mission to make affordable vaccines accessible worldwide. Present across 170+ countries, including the U.S., the UK, and Europe, SII operates one of the largest multifunctional vaccine production facilities in Manjri, Pune, with an annual capacity of 4 billion doses, contributing to saving over 30 million lives over the years. For more information, visit www.seruminstitute.com.

Contact investors:
Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com
US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03

¹ World Health Organization (WHO). Chikungunya.https://www.who.int/news-room/fact-sheets/detail/chikungunya   

² European Centre for Disease Prevention and Control. Chikungunya virus disease. https://www.ecdc.europa.eu/en/chikungunya-virus-disease.

³ European Centre for Disease Prevention and Control. Chikungunya virus disease worldwide overview. https://www.ecdc.europa.eu/en/chikungunya-monthly.

⁴ Pan American Health Organization (PAHO). Chikungunya: analysis by country.  https://www.paho.org/en/arbo-portal/chikungunya-data-and-analysis/chikungunya-analysis-country

⁵ Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701.

Attachment

• Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

Propr® Introduces Propr Paste, Completing Its Clinically Inspired System for Gentle, Long-Term Oral Health




Propr® Introduces Propr Paste, Completing Its Clinically Inspired System for Gentle, Long-Term Oral Health

New York, NY, March 11, 2026 (GLOBE NEWSWIRE) — Propr®, the fluoride free oral care brand founded by leading periodontist and educator Dr. Jack Gruber, today announced the launch of Propr Paste, the third product in the Propr family and a key milestone in the brand’s mission to redefine everyday oral hygiene through gentler, smarter design.

Propr’s product journey began with the Propr Brush, a revolutionary toothbrush designed to eliminate abrasive nylon bristles in favor of Medical Grade TPE super-soft scrubbers that clean effectively while protecting teeth and gums. The brand then expanded into interdental care with Propr Picks, offering a more forgiving alternative to traditional floss and rigid plastic picks that can contribute to gum irritation when used daily.

With the introduction of Propr Paste, the brand now delivers a complete oral care system designed to work in harmony, addressing brushing, interdental cleaning, and toothpaste formulation through a single, clinically informed philosophy.

“Most oral care products are developed in isolation,” said Dr. Gruber. “We designed Propr as a system because the mouth experiences everything together, twice a day, every day.”

Traditional toothpastes often rely on abrasive agents to achieve a strong cleaning sensation. Over time, repeated exposure to these abrasives, especially when paired with aggressive brushing tools, can contribute to gum irritation and enamel wear. Propr Paste was developed to avoid this cycle.

Formulated to be non-abrasive and gum-friendly, Propr Paste supports effective plaque removal while minimizing disruption to delicate oral tissues. When paired with the Propr Brush and Propr Picks, it helps users maintain cleanliness without compounding daily stress on teeth and gums.

Key benefits of Propr Paste include:

• Gentle, effective daily cleansing
• Reduced cumulative wear on enamel and gum tissue
• Seamless compatibility with Propr Brush and Propr Picks
• Designed for sensitive mouths and long-term use

Propr Paste is suitable for adults and children alike, as well as individuals with gum sensitivity, periodontal concerns or dental restorations. Its formulation reflects Propr’s broader commitment to preventive care, focusing on preservation rather than aggressive intervention.

“The goal isn’t to scrub harder,” Dr. Gruber added. “It’s to care better, over a lifetime.”

The launch of Propr Paste marks a significant step forward for Propr as it continues to expand its ecosystem of oral care solutions rooted in clinical experience and material innovation.

Propr Paste is now available for purchase. To learn more about Propr and its growing family of oral care products, visit proprdental.com.

About Propr®
Propr is an oral care company founded on the belief that better tools lead to better health. Invented by periodontist Dr. Jack Gruber, Propr develops innovative products designed to protect teeth and gums while supporting lifelong oral wellness.

CONTACT: Media Contact:
Alexis Schwartz
alexis@proprdental.com

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment




Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

$250,000 top award goes to Connor Hill in America’s longest running and most distinguished science and math competition

TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Connor Hill, 17, of State College, Pennsylvania, won the top award of $250,000 in the 2026 Regeneron Science Talent Search (STS), the U.S.’s oldest and most prestigious science and math competition for high school seniors.

Key Takeaways:

• This year marks the 85th anniversary of the Science Talent Search and Regeneron’s 10^th year as the title sponsor; Regeneron is extending its title sponsorship through 2036, pledging $150 million to fuel the next generation of science and technology leaders.
• Forty finalists were honored at the National Building Museum in Washington, D.C., receiving more than $1.8 million in awards recognizing groundbreaking research, exceptional analytical rigor, exceptional problem-solving skills and potential to shape the future of STEM.
• Top Three Winners:
  
  • Connor Hill, 17, of State College, Pennsylvania won first place and $250,000 for discovering a way to identify all the possible “noble polyhedra,” highly symmetric shapes with flat sides and straight edges. He wrote a computer program to do the computations and proved there are two infinite families of noble polyhedra, as well as 146 isolated examples.

• • Second place and $175,000 went to Edward Kang, 17, of Hackensack, New Jersey for using retinal images to train AI models on subtle patterns linked to autism and attention-deficit/hyperactivity disorder to create a screening tool called RetinaMind. He also created retinal cell models to study gene changes that may help explain why these differences occur.
  • Third place and $150,000 went to Iris Shen, 17, of The Woodlands, Texas, for testing a potential cancer drug in clams to see if they could serve as an animal model for blood cancer drug discovery. In the clams, the drug had a similar effect to what researchers observe in human cells. She also tested a mix of other potential cancer drugs, which slowed the clams’ tumor growth.

• Media Resources:
  • High-resolution photos, winner bios, project summaries, b-roll, and video interviews are available in the 2026 Regeneron Science Talent Search Media Kit: https://www.societyforscience.org/2026-regeneron-science-talent-search-media-kit
  • Media may also access the full list of 40 finalists and detailed project descriptions at: https://www.societyforscience.org/regeneron-sts/2026-student-finalists/
  • The Science Talent Search represents a long-term commitment to the next generation of scientific leadership. It supports students’ educational pursuits and research while recognizing young scientists whose intellectual rigor and bold thinking position them to shape the future of innovation.
  • Together, all 40 finalists join a distinguished group of Science Talent Search alumni, many of whom have gone on to achieve world-changing careers in STEM, including earning esteemed honors such as 13 Nobel Laureates, 23 MacArthur Fellowships and 14 winners of the National Medal of Science.

“Congratulations to the winners of this year’s Regeneron Science Talent Search,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. “Their bold vision and perseverance reveal what the next generation of problem solvers truly looks like—and why our future is in capable hands. Their creativity, ambition and courage to confront the world’s toughest challenges are exactly what this moment demands.”

The Regeneron Science Talent Search is committed to providing a national platform for high school seniors to showcase original, innovative STEM research that proposes novel solutions to real-world issues. Finalists are evaluated for their scientific rigor, originality, critical thinking, leadership potential, and commitment to creating meaningful impact in crucial STEM fields.

“Congratulations to the winners of the 2026 Regeneron Science Talent Search, and to all the finalists who participated in this year’s competition. These students represent exactly the kind of extraordinary talent scientific progress depends on,” said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chairman, President and Chief Scientific Officer of Regeneron and a 1976 Science Talent Search winner. “From my own experience as a Science Talent Search winner, I know the transformative power of this competition. That’s why Regeneron is deepening our commitment and extending our title sponsorship for another decade. Through our support of Science Talent Search and our title sponsorship of the Regeneron International Science Fair, the world’s largest high school science competition, we will invest more than $300 million from 2017 to 2036. We may never know where the next great scientific leader will come from, but we do know it’s our responsibility to find that talent, fuel it, and give it every chance to change the world.”

Other top honors from the competition include:

• Fourth Place and $100,000: Rachel Chen, 18, of Los Angeles, California for developing a concrete, visual way to describe systems of many quantum particles using Temperley-Lieb diagrams, expanding on a 1997 finding. Rachel illustrated how a magnetic field influences the entire quantum system using these simple point-and-line diagrams.
• Fifth Place and $90,000: Jerry Xu, 17, of Lexington, Massachusetts for building an AI program that compresses the features of protein molecules into strings of numbers. He showed that his model enabled a more efficient comparison of protein structure without the loss of important features. This could speed up genetic research and drug discovery.
• Sixth Place and $80,000: Leanne Fan, 18, of San Diego, California for building a device to simulate microgravity in order to study how wounds heal in space. With the device, she tested red light on injured flatworms and found that it sped up tissue regeneration by 95.2%. She also found that red light treatment speeds up wound repair in human models in normal gravity.
• Seventh Place and $70,000: Claire Jiang, 18, of Wyckoff, New Jersey for developing a cellular model of juvenile idiopathic arthritis (JIA). She treated cells used to study rheumatoid arthritis with bone morphogenetic protein 4, a protein linked to JIA joint damage. Her experiments showed they acted like JIA cells in their growth and gene expression.
• Eighth Place and $60,000: Leon Wang, 17, of Stamford, Connecticut, for finding two FDA-approved drugs that may also be effective against Alzheimer’s disease. Both drugs reduce the activity of a cellular signaling pathway linked to an Alzheimer’s gene. In lab-grown brain cells, the drugs reduced signs of damage due to the pathway.
• Ninth Place and $50,000: Jonathan Du, 18, of Mountain View, California for investigating the unrestricted finite factorization property. Factorization breaks down mathematical objects into simpler parts. Jonathan’s work explores complicated algebraic systems where some elements have several factorizations, and others do not factor at all.
• Tenth Place and $40,000: Seth Nabat, 18, of Winnetka, California for building a machine learning program to quickly and accurately track particle collisions without sacrificing accuracy by favoring symmetry. Seth’s program uses an unconstrained network to catch errors, and another network to find patterns in them.
• Colin Jie Chu, 18, of Palo Alto, California was named the Seaborg Award winner and selected to speak on behalf of the Regeneron Science Talent Search Class of 2026. The 40 finalists chose Colin as the person who best exemplifies their class and the legacy of nuclear chemist Glenn T. Seaborg, who won the Nobel Prize for Chemistry in 1951 and served on the Society’s Board of Trustees for 30 years.
• The remaining 30 finalists received $25,000 each. In total, Regeneron awarded $3.1 million in awards, including $2,000 to each top scholar and their school. Since the start of Regeneron’s sponsorship in 2017 through this year’s competition, Regeneron and the Society have engaged and inspired more than 20,000 of the nation’s top young scientists, recognized 3,000 as Regeneron scholars, and awarded over $31 million in prizes.

Resources:

• 2026 Winner Media Kit (photos, bios, research summaries, b-roll, video)
• Virtual Project Showcase (All 40 finalist projects)
• Full List of 40 Finalists
• Top 300 Scholars
• Notable STS Alumni

What is the Regeneron Science Talent Search?

The Regeneron Science Talent Search, a program of Society for Science since 1942, is the United States’ oldest and most prestigious science and math competition for high school seniors. This year, more than 2,600 students submitted original research in critical scientific fields and were judged by leading experts. Unique among high school competitions in the U.S. and globally, the Regeneron Science Talent Search identifies and supports the U.S.’s most promising future leaders in science as they develop innovative solutions to solve significant global challenges through rigorous research and discoveries. The program provides students with a national stage to present new ideas and challenge conventional ways of thinking.

For over eight decades, the Science Talent Search has rewarded talented high school seniors who dedicate countless hours to original research projects and present their results in rigorous reports that resemble graduate school theses. Collectively, STS alumni have received millions of dollars in scholarships and gone on to be awarded Nobel Prizes, Fields Medals, MacArthur Fellowships and numerous other accolades.

What is Regeneron’s role?

For Regeneron, the Science Talent Search is a deeply personal commitment, as its co-Founders George D. Yancopoulos, M.D., Ph.D. and Leonard S. Schleifer, M.D., Ph.D. began their scientific careers as Science Talent Search participants. In 2017, Regeneron became the third long-term sponsor of the Science Talent Search, succeeding Westinghouse and Intel, with a 10-year, $100 million commitment to help reward and celebrate the best and brightest young minds. Since the beginning of this enduring sponsorship, through this year’s Science Talent Search, Regeneron and the Society have engaged and inspired more than 20,000 of the nation’s top young scientists, recognized 3,000 as Regeneron Scholars, and awarded over $31 million in prizes. In February 2026, the company renewed its sponsorship for another decade, increasing its investment by 50%, pledging an additional $150 million. Regeneron is also the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), a program of the Society and the world’s largest high school science competition. Regeneron’s support for these two premier programs totals more than $300 million from 2017 to 2036.

Learn more at https://www.societyforscience.org/regeneron-sts/ or www.regeneron.com/STEM

What is Society for Science?

Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its STEM Outreach programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire.

Learn more at www.societyforscience.org and follow us on Facebook, X, Instagram, and LinkedIn.

What is Regeneron?

Regeneron is a leading biotechnology company that invents, develops, and commercializes potentially life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence, and to build sustainable communities. Our most significant philanthropic investments are in science education, a commitment we call STEM-Fueled™ – our collection of programs and partnerships, including the Regeneron Science Talent Search (STS) and the Regeneron International Science and Engineering Fair (ISEF), that fuel future scientific innovators to pursue bold ideas and advance world-changing solutions. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono, and matching gift programs. We are proud to be recognized on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the United States.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Media Contacts:
Gayle Kansagor, Society for Science
703-489-1131, gkansagor@societyforscience.org

Tina Parisi Tuttle, Regeneron
973-975-9357, tina.parisituttle@regeneron.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a58bf3ac-2d0f-41db-9885-3340508eac33

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering




Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the pricing of its previously announced upsized underwritten public offering of 7,313,582 shares of its common stock at a public offering price per share of $81.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a public offering price of $80.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering are expected to be approximately $625 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Dianthus, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on March 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Dianthus has granted the underwriters a 30-day option to purchase up to an additional 1,157,407 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by Dianthus.

Dianthus intends to use the net proceeds from this offering to advance the Company’s clinical and preclinical development activities, commercial readiness activities as well as for working capital and general corporate purposes.

Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair are acting as joint book-running managers for the offering. LifeSci Capital is acting as Dianthus’ financial advisor.

The offering is being made pursuant to a shelf registration statement on Form S-3 relating to the securities that was previously filed with the Securities and Exchange Commission (“SEC”) and declared effective on January 30, 2026 and a related registration statement that was filed with the SEC on March 10, 2026 pursuant to Rule 462(b) under the Securities Act of 1933, as amended (and became automatically effective upon filing). This offering is being made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov, and, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding Dianthus’ expectations regarding the consummation of the offering, the satisfaction of customary closing conditions with respect to the offering and the potential value and clinical benefit of the Company’s product candidates. The words “opportunity,” “potential,” “milestones,” “runway,” “will,” “anticipate,” “achieve,” “near-term,” “catalysts,” “pursue,” “pipeline,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart and DNTH212 and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the development of claseprubart, DNTH212 or the Company’s other compounds may take longer and/or cost more than planned, that the Company or its partner may be unable to successfully complete the clinical development of the Company’s compounds, that the Company or its partner may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company’s compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering




Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the pricing of its upsized underwritten public offering of 10,526,317 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 877,194 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $57.00 per common share and the pre-funded warrants are being offered at a price of $56.9999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $650.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,710,526 common shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about March 12, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair are acting as joint book-running managers for the offering. Baird is acting as lead manager for the offering.

An automatically effective shelf registration statement relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2024. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, telephone: (415) 364-2720 or by emailing syndprospectus@stifel.com; RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, New York, NY 10281, by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

No securities are being offered or sold, directly or indirectly, in Canada or to any resident of Canada.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact and include statements regarding the anticipated closing of the public offering. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the SEC and the securities commissions in British Columbia, Alberta and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent K_V7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K_V7 and Na_V1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts.

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.

Investor Contact:
Tucker Kelly
Chief Financial Officer
Email: investors@xenon-pharma.com

Source: Xenon Pharmaceuticals Inc.